TODAY OUR GUEST IS Dr Kathy Mngadi, Protocol co-chair and Principal Investigator for the Aurum Tembisa C4 site for the Imbokodo protocol.

• A study analysing whether an experimental HIV vaccine regimen was safe and able to prevent HIV infection will not progress further.
• This follows data that the experimental vaccine did not effectively prevent HIV acquisition however, no significant safety concerns were identified throughout the trial.
• Launched in November 2017, the Imbokodo Study, reached full enrollment in 2019, and completed vaccinations in June 2020.
• The primary aim of the study was to evaluate the experimental regimen in approximately 2,600 women between ages 18 and 35 across five sub-Saharan Africa countries including: Malawi, Mozambique, South Africa, Zambia and Zimbabwe.
• In preclinical studies, regimens with mosaic-based vaccines elicited a strong immune response associated with protection against HIV in monkeys.
• Findings from two early-stage human clinical trials also suggested these vaccine were well tolerated and could generate anti-HIV responses in healthy adult volunteers, increasing hope for good results in the Imbokodo trial.